Fluzoparib
- Generic Name
- Fluzoparib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H16F4N6O2
- CAS Number
- 1358715-18-0
- Unique Ingredient Identifier
- TWF0ML1CK8
- Background
Fluzoparib is under investigation in clinical trial NCT03863860 (A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients).
- Indication
⑴适用于既往经过二线及以上化疗的伴有胚系BRCA突变(gBRCAm)的铂敏感复发性卵巢癌、输卵管癌或原发性腹膜癌患者的治疗。⑵适用于铂敏感的复发性上皮性卵巢癌、输卵管癌或原发性腹膜癌成人患者在含铂化疗达到完全缓解或部分缓解后的维持治疗。
- Associated Conditions
- -
- Associated Therapies
- -
Bioequivalence of Fluzoparib(SHR3162) Study on Healthy Chinese Adult Subjects
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2020-08-20
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT04521192
- Locations
- 🇨🇳
The affiliated hospital of QingDao university, Qingdao, Qingdao, China
A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients
- First Posted Date
- 2020-08-18
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 142
- Registration Number
- NCT04517357
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Resectable Pancreatic Cancer
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2020-12-31
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 74
- Registration Number
- NCT04425876
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-05-22
- Last Posted Date
- 2023-02-13
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 25
- Registration Number
- NCT04400188
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
- First Posted Date
- 2020-03-09
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 5
- Registration Number
- NCT04300114
- Locations
- 🇨🇳
West China Hospital, Chengdu, Sichuan, China
🇨🇳The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
🇨🇳Chinese PLA General Hospital, Beijing, Beijing, China
A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation
- First Posted Date
- 2020-03-05
- Last Posted Date
- 2020-08-10
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 474
- Registration Number
- NCT04296370
- Locations
- 🇨🇳
Jiangsu HengRui Medicine Co., Ltd., Shanghai, China
A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 690
- Registration Number
- NCT04229615
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-01-14
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 39
- Registration Number
- NCT04228601
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
🇨🇳Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China
Effect of Fluconazole on PK of Fluzoparib in Healthy Male Subjects
- First Posted Date
- 2019-12-10
- Last Posted Date
- 2019-12-10
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT04193319
- Locations
- 🇨🇳
Early Cancer Research Center of Hunan Cancer Hospital, Hunan, Hunan, China
Effect of Omeprazole on PK of Fluzoparib in Healthy Male Subjects
- First Posted Date
- 2019-09-30
- Last Posted Date
- 2022-07-29
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT04108676
- Locations
- 🇨🇳
The third xiangya hospital Hospital,of central south university, Changsha, Hunan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.